Cancer Therapy Advisor7 小时
Data Show Continued Benefit With Frontline Asciminib in Ph+ CML-CP
Asciminib continued to improve outcomes when compared to investigator-selected TKIs in patients with newly diagnosed, Ph+ CML-CP in the ASC4FIRST trial.
Cancer Therapy Advisor7 小时
Billing for Patient Portal Messages Decreases Use of Messaging
Billing for patient portal messages is associated with a modest decrease in patient-initiated message volume, data suggest.